Physician profile
Guy L Culpepper
NPI 1407849052
$3,299.37
in general payments reported to CMS, 2019-2025
39 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $253 · 2021: $32.44 · 2022: $191 · 2023: $989 · 2024: $474 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,207.62 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $179.18 | 2019-2023 | Mounjaro |
| Pfizer INC. | $171.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.63 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $150.21 | 2019 | |
| Stryker Corporation | $149.19 | 2022 | |
| Amgen INC. | $122.82 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $111.17 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Corium, LLC | $100.88 | 2024 | Azstarys |
| Gilead Sciences, INC. | $85.88 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $65.53 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $58.27 | 2019 | |
| Amarin Pharma, INC. | $56.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.74 | 2019-2020 | |
| Dexcom, INC. | $50.64 | 2024-2025 | Dexcom G6 Transmitter |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Culpepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.